FaMRIsc trial shows: MRI breast screening for women with ≥20% lifetime risk is also cost-effective in Europe. Issue 2 (February 2021) - Tilanus-Linthorst, Madeleine; Geuzinge, A.; Obdeijn, I.M.; Rutgers, E.; Mann, R.; Saadatmand, S.; de Roy van Zuidewijn, D.; Oosterwijk, J.; Tollenaar, R.; Ausems, M.; van 't Riet, M.; Margrethe, S.V.; et al.